Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will publish the dates of the consultation period with pharmaceutical companies, as agreed at the Commission on Human Medicines Antidepressant Risk Minimisation Expert Working Group meeting on 1 May.

The Medicines and Healthcare products Regulatory Agency (MHRA) will seek the advice of the independent Commission on Human Medicines (CHM) on the final recommendations of the Antidepressant Risk Minimisation Expert Working Group, following the next meeting in July 2025.

If the CHM advises the MHRA to request changes to the antidepressant product information, the MHRA will write to all of the pharmaceutical companies affected in accordance with standard timelines and procedures for requesting variations to product information.